Functional partial agonism at ionotropic excitatory amino acid receptors

Neurochemistry International

Volumn 29, Issue 3, 1996, Pages 309-316

  Ebert, Bjarke ^a   Madsen, Ulf ^a   Søby, Karina K ^a   Krogsgaard Larsen, Povl ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; EXCITATORY AMINO ACID RECEPTOR; PARTIAL AGONIST;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; COMPARATIVE STUDY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; NONHUMAN; PHARMACOLOGY; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

AMOA; ANIMALIA;

EID: 0030248177     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-0186(95)00151-4     Document Type: Article

References (39)

1. 2-adrenoceptor. Nature. 374:1995;272-276.
2. Bowen D.M. Neurotransmitters in Alzheimer's disease. Age. 11:1988;104-110.
3. Bowen D.M. Treatment of Alzheimer's disease. Molecular pathology versus neurotransmitter-based therapy. Br. J. Psychiat. 157:1990;327-330.
4. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
5. Christensen I.T., Reinhardt A., Nielsen B., Ebert B., Madsen U., Nielsen E.Ø., Brehm L., Krogsgaard-Larsen P. Excitatory amino acid agonists and partial agonists. Drug Des Del. 5:1989;57-71.
6. Colquhoun D. (1973) The relation between classical and cooperative models for drug action. In Drug Receptors (Rang H., Ed.), pp. 149-181. MacMillan, London.
7. Deutsch S.I., Mastropaolo J., Schwartz B.L., Rosse R.B., Morihisa J.M. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin. Neuropharmac. 12:1989;1-13.
8. Deutsch S.I., Morihisa J.M. Glutamatergic abnormalities in Alzheimer's disease and a rationale for clinical trials with L-glutamate. Clin. Neuropharmac. 11:1988;18-35.
9. Drejer J. (1992) Therapeutic opportunities in modulators of excitatory amino acid-mediated neurotransmission. In Excitatory Amino Acid Receptors: Design of Agonists and Antagonists (Krogsgaard-Larsen P. and Hansen J. J., Eds), pp. 352-375. Ellis Horwood, Chichester.
10. Ebert B., Lenz S.M., Brehm L., Bregnedal P., Hansen J.J., Frederiksen K., Bøgesø K.P. and Krogsgaard-Larsen P. (1994a) Resolution, absolute stereochemistry and pharmacology of the S-(+)- and R-(-)-isomers of the apparent partial AMPA receptor agonist (R,S)-2-amino-3-(3-hydroxy-5-phenylisoxazol-4-yl)propionic acid [(R,S)-APPA]. J. Med. Chem. 37, 878-884.
11. Ebert B., Madsen U., Lund T.M., Holm T., Krogsgaard-Larsen P. Molecular pharmacology of cortical and spinal AMPA receptors. Molec. Neuropharmac. 2:1992;47-49.
12. Ebert B., Madsen U., Lund T.M., Lenz S.M., Krogsgaard-Larsen P. Molecular pharmacology of the AMPA agonist (S)-2-amino-3-(3-hydroxy-5-phenyl-4-isoxazolyl)propionic acid [(S)-APPA] and the AMPA antagonist, (R)-APPA. Neurochem. Int. 24:1994;507-515.
13. Ebert B., Søby K.K., Madsen U. and Krogsgaard-Larsen P. (1995) Glutamic acid receptors in schizophrenia and Alzheimer's disease: functional partial agonism and receptor modulation as potential therapeutic approaches. In Schizophrenia - An Integrated View (Fog R., Gerlach J. and Hemmingsen R., Eds), pp. 379-398. Munksgaard, Copenhagen.
14. Greenamyre J.T. The role of glutamate in neurotransmission and in neurologic disease. Arch. Neurol. 43:1986;1058-1064.
15. Greenamyre J.T. Neuronal bioenergetic defects, excitotoxicity and Alzheimer's disease - use it and lose it. Neurobiol. Aging. 12:1991;334-336.
16. Greenamyre J.T., Maragos W.F. Neurotransmitter receptors in Alzheimer disease. Cerebr. Brain Metab. Rev. 5:1993;61-94.
17. Greenamyre J.T., Young A.B. Excitatory amino acids and Alzheimer's disease. Neurobiol. Aging. 10:1989;593-602.
18. Hansen J.J., Krogsgaard-Larsen P. Isoxazole amino-acids as glutamic acid agonists. Synthesis of some analogues and homologues of ibotenic acid. J. Chem. Soc. Perkin Trans. I:1980;1826-1833.
19. Harrison N.L., Simmonds M.A. Quantitative studies on some antagonists of N-methyl- D-aspartate in slices of rat cerebral cortex. Br. J. Pharmac. 84:1985;381-391.
20. Koh J., Yang L.L., Cotman C.W. β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:1990;315-320.
21. Kowall N.W., Beal M.F., Busciglio J., Duffy L.K., Yankner B.A. An in vivo model for the neurodegenerative effects of β-amyloid and protection by substance P. Proc. Natl. Acad. Sci. U.S.A. 88:1991;7247-7251.
22. Krogsgaard-Larsen P., Ferkany J.W., Nielson E.Ø., Mdsen U., Ebert B., Johansen J.S., Diemer N.H., Bruhn T., Beattie D.T., Curtis D.R. Novel class of amino acid antagonists at non-N-methyl- D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology and neuroprotection. J. Med. Chem. 34:1991;123-130.
23. Krogsgaard-Larsen P. Honoré T., Hansen J.J., Curtis D.R. and Lodge D. New class of glutamate agonist structurally related to ibotenic acid. Nature (Lond.). 284:1980;64-66.
24. Lauridsen J., Honoré T., Krogsgaard-Larsen P. Ibotenic acid analogues. Synthesis, molecular flexibility, and in vitro activity of agonists and antagonists at central glutamic acid receptors. J. Med. Chem. 28:1985;668-672.
25. Lazareno S., Birdsall N.J.M. Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br. J. Pharmac. 109:1993;1110-1119.
26. Leatherbarrow R.J. (1992) Graft Version 3.0. Staines, U.K.: Erithacus Software.
27. Leff P. The two-state model of receptor activation. Trends Pharmac. Sci. 16:1995;89-97.
28. Maragos W.F., Greenamyre J.T., Penney J.B., Young A.B. Glutamate dysfunction in Alzheimer's disease: an hypothesis. Trends Neurosci. 10:1987;65-68.
29. Marx J. New clue found to Alzheimer's. Science. 253:1991;857-858.
30. Monod J., Wyman J., Changeux J.-P. On the nature of allosteric transitions: a plausible model. J. Molec. Biol. 12:1965;88-118.
31. Plaitakis A., Caroscio J.T. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 22:1987;575-579.
32. Roberts G.W., Bruton C.J. Notes from the graveyard: neuropathology and schizophrenia. Neuropathol. Appl. Neurobiol. 16:1990;3-16.
33. Schild H.O. pA, a new scale for the measurement of drug antagonism. Br. J. Pharmac. 2:1947;189-206.
34. x and competitive drug antagonism. Br. J. Pharmac. 4:1949;277-280.
35. Sheardown M.J., Nielsen E. Ø, Hansen A.J., Jacobsen P., Honoré T. 2,3-Di-hydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline A neuroprotectant for cerebral ischemia. Science. 247:1990;571-574.
36. Simon R.P., Swan J.H., Griffiths T., Meldrum B.S. Blockade of NMDA-receptors may protect against ischemic damage in the brain. Science. 226:1984;850-852.
37. Ulas J., Cotman C.W. Excitatory amino acid receptors in schizophrenia. Schizophrenia Bull. 19:1993;105-117.
38. Watkins J. C. and Collingridge G. L., (Eds.) (1989) The NMDA Receptor. Oxford University Press, Oxford.
39. Weiss J.H., Choi D.W. Differential vulnerability to excitatory amino acid-induced toxicity and selective neuronal loss in neurodegenerative diseases. Can. J. Neurol. Sci. 18(3, suppl.):1991;394-397.